{
    "clinical_study": {
        "@rank": "28636", 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94\n      in patients who previously have used anti-HIV drugs."
        }, 
        "brief_title": "A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT\n      tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  CD4 count greater than 50 cells/mm3.\n\n          -  HIV RNA less than 50,000 copies/ml.\n\n          -  No active AIDS (excluding CD4 count less than 200 cells/mm3).\n\n          -  Ability to comply with dosing schedule and protocol evaluations.\n\n        Prior Medication:\n\n        Allowed:\n\n        AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Active AIDS (not excluding CD4 count less than 200).\n\n          -  Malabsorption syndrome affecting drug absorption.\n\n          -  Serious medical condition that would compromise safety of the patient.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  AZT or NNRTIs.\n\n          -  More than 1 week treatment with any protease inhibitor.\n\n          -  Enrollment in any other investigational drug protocol.\n\n        Patients with the following prior conditions are excluded:\n\n        History of clinically relevant pancreatitis or hepatitis within the past 6 months.\n\n        Required:\n\n        Antiretroviral therapy with either single or double reverse transcriptase inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002217", 
            "org_study_id": "280D", 
            "secondary_id": [
                "UNAP 12", 
                "NZTA 4005"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Lamivudine/Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Abacavir", 
                "Lamivudine, zidovudine drug combination", 
                "Amprenavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Patient Compliance", 
            "Anti-HIV Agents", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15213"
                }, 
                "name": "Anderson Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "citation": "Henry K, Shaeffer M, Ross L, Johnson M, Fisher R, Liao Q, Graham N. Response to Combivir and abacavir given bid to nucleoside experienced patients is not affected by the presence of the M184V mutation. 6th Conf Retro and Opportun Infect. 1999 Jan 31 - Feb 4 (abstract no 132)"
            }, 
            {
                "PMID": "11170982", 
                "citation": "Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q, Shaefer MS; TARGET Study Team. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 2001 Feb 15;183(4):571-8. Epub 2001 Jan 11."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002217"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "Anderson Clinical Research": "40.441 -79.996"
    }
}